Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Comprehensive DNA testing uncovers hidden deletions, missing pieces of genetic code that are far too small to appear on a standard chromosome study, by using tools such as chromosomal microarray, MLPA, and next-generation sequencing with copy number variant analysis. Geneticists measure the quantity of DNA at thousands of points across the genome and compare it to a reference, flagging any region that shows only one copy where two are expected, then confirm the finding and check whether it was inherited or newly arising. Several factors shape which method actually catches a deletion, including its size, its location, and how the surrounding genes behave, so see below for the complete answer and the details that matter most before you draw conclusions.
If symptoms in you or your child are what led you here, mapping those symptoms is a practical first step while genetic questions are being sorted out. Take a free, instant, online symptom check to see which patterns your symptoms fit, what a clinician may look for, and how to prepare for the next conversation about testing.
Last reviewed for medical accuracy: 08/18/2026
The Science of Comprehensive DNA Testing: How Geneticists Detect Hidden Deletions
Comprehensive DNA testing has revolutionized our understanding of genetic disorders. One gene that often comes under scrutiny is the PHEX gene, mutations or deletions of which can lead to conditions like X-linked hypophosphatemic rickets. Detecting hidden deletions—segments of DNA missing from a gene—requires a blend of advanced laboratory techniques and expert analysis. Below, we explore how geneticists uncover these elusive changes through PHEX gene sequencing and deletion analysis.
• Silence or truncate the PHEX protein, disrupting phosphate regulation
• Lead to chronic symptoms if not diagnosed and managed early
• Be missed by standard “single‐exon” tests if they span multiple exons or regulatory regions
Understanding and detecting these hidden deletions is key to accurate diagnosis, appropriate treatment and genetic counseling.
• Blood draws—standard method with high DNA yield
• Saliva kits—noninvasive, convenient for at-home testing
• Tissue biopsies—when mosaicism or tumor DNA is under investigation
Once collected, DNA is purified to remove proteins and contaminants. High‐integrity DNA ensures reliable downstream analysis.
• Targeted panels isolate PHEX exons and flanking regions
• Library preparation attaches adapters for sequencing
• High-throughput machines read millions of fragments in parallel
NGS excels at identifying single nucleotide variants (SNVs) and small insertions/deletions (indels) within PHEX. However, large deletions or multi‐exon losses can escape detection due to coverage variability.
• Multiplex Ligation-dependent Probe Amplification (MLPA)
– Probes bind specific exons of PHEX
– Quantitative readout reveals copy-number changes exon by exon
• Quantitative PCR (qPCR)
– Targets suspected deletion breakpoints
– Compares amplification levels to reference DNA
• Comparative Genomic Hybridization (array CGH)
– Scans the genome for gains and losses at high resolution
– Detects deletions as small as a few kilobases
• Long-Read Sequencing (PacBio, Oxford Nanopore)
– Reads continuous DNA stretches >10 kb
– Maps complex rearrangements and deep intronic deletions
By combining these approaches, laboratories maximize sensitivity—ensuring that both subtle and extensive PHEX deletions are detected.
• Alignment
– Sequencing reads are mapped to the human reference genome
– Gaps or drops in coverage indicate potential deletions
• Variant Calling
– Algorithms flag differences in copy number and sequence
– Quality filters remove false positives from low-coverage regions
• Clinical Annotation
– Databases (ClinVar, HGMD) help classify variants as pathogenic or benign
– Intragenic deletions are assessed for their impact on PHEX function
Geneticists and molecular pathologists review these findings in the context of the patient’s clinical history and family pedigree.
• Targeted Therapy
– Phosphate supplements and active vitamin D analogs
– Emerging treatments like FGF23 antibodies
• Monitoring
– Regular assessment of bone density and growth
– Blood tests for phosphate, calcium and kidney function
• Family Screening
– Female carriers may have milder symptoms yet still pass deletions to children
– Early testing in at-risk relatives guides timely intervention
Recognizing a deletion can transform a “mystery” diagnosis into a clear care plan.
• Explains inheritance patterns and recurrence risks
• Discusses reproductive options—preimplantation genetic testing (PGT), prenatal diagnosis
• Provides psychosocial support for families adjusting to a genetic diagnosis
Counselors ensure that patients understand test results, their limitations and next steps.
Taking Control: When to Seek Help
If you or a loved one experiences persistent bone pain, unusual fractures or growth delays, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you identify possible causes and guide you on whether to pursue genetic testing.
Next Steps and Professional Guidance
Genetic testing is a powerful tool—but it’s only one piece of your health puzzle. Always:
• Speak to a doctor about any life-threatening or serious symptoms
• Review genetic test results with a healthcare provider or genetic counselor
• Stay informed about new testing methods and treatment options
Comprehensive PHEX gene sequencing and deletion analysis have unlocked answers for many families. By understanding how hidden deletions are detected, patients can move from uncertainty to targeted care—improving outcomes and quality of life.
(References)
* Percy AK. Nothing out of sequence?: think deletion! Neurology. 2007 Mar 27;68(13):975-6. doi: 10.1212/01.wnl.0000260457.42141.30. PMID: 17389299.
* Kubisch C. Chromosomal microdeletions: minor imbalances with major consequences. Neurology. 2009 Mar 3;72(9):782-3. doi: 10.1212/01.wnl.0000338350.68544.06. Epub 2008 Dec 10. PMID: 19073943.
* Stheneur C, Collod-Béroud G, Faivre L, Buyck JF, Gouya L, Le Parc JM, Moura B, Muti C, Grandchamp B, Sultan G, Claustres M, Aegerter P, Chevallier B, Jondeau G, Boileau C. Identification of the minimal combination of clinical features in probands for efficient mutation detection in the FBN1 gene. Eur J Hum Genet. 2009 Sep;17(9):1121-8. doi: 10.1038/ejhg.2009.36. Epub 2009 Mar 18. PMID: 19293843; PMCID: PMC2986588.
* Jedrzejowska M, Milewski M, Zimowski J, Zagozdzon P, Kostera-Pruszczyk A, Borkowska J, Sielska D, Jurek M, Hausmanowa-Petrusewicz I. Incidence of spinal muscular atrophy in Poland--more frequent than predicted? Neuroepidemiology. 2010;34(3):152-7. doi: 10.1159/000275492. Epub 2010 Jan 15. PMID: 20090376.
* Møller LB, Hicks JD, Holmes CS, Goldstein DS, Brendl C, Huppke P, Kaler SG. Diagnosis of copper transport disorders. Curr Protoc Hum Genet. 2011 Jul;Chapter 17:Unit17.9. doi: 10.1002/0471142905.hg1709s70. PMID: 21735378; PMCID: PMC3156244.
* Hori I, Kawamura R, Nakabayashi K, Watanabe H, Higashimoto K, Tomikawa J, Ieda D, Ohashi K, Negishi Y, Hattori A, Sugio Y, Wakui K, Hata K, Soejima H, Kurosawa K, Saitoh S. CTCF deletion syndrome: clinical features and epigenetic delineation. J Med Genet. 2017 Dec;54(12):836-842. doi: 10.1136/jmedgenet-2017-104854. Epub 2017 Aug 28. PMID: 28848059.
* Ramírez-Velazco A, Domínguez-Quezada MG. [Atypical deletions in Williams-Beuren syndrome]. Rev Med Inst Mex Seguro Soc. 2017 Sep-Oct;55(5):615-620. PMID: 29193944.
* Shaffer LG. Special issue on canine genetics: animal models for human disease and gene therapies, new discoveries for canine inherited diseases, and standards and guidelines for clinical genetic testing for domestic dogs. Hum Genet. 2019 May;138(5):437-440. doi: 10.1007/s00439-019-02025-5. Epub 2019 May 5. PMID: 31056728.
* Meossi C, Carrer A, Ciaccio C, Pezzoli L, Pezzani L, Silipigni RM, Sciacca FL, Tenconi R, Esposito S, De Laurentiis A, Pantaleoni C, Marchisio P, Natacci F, D'Arrigo S, Iascone M, Milani D. Looks Can Be Deceiving: Diagnostic Power of Exome Sequencing in Debunking 15q11.2 Copy Number Variations. Genes (Basel). 2024 Nov 7;15(11). doi: 10.3390/genes15111441. Epub 2024 Nov 7. PMID: 39596641; PMCID: PMC11594224.
* Zanobio M, Nardecchia F, Cappuccio G, Onore ME, Di Letto P, Rahman SI, Terrone G, Ugga L, De Giorgi A, Cas MD, Trinchera M, Leuzzi V, Piluso G, Nigro V, Brunetti-Pierri N, TUDP consortium, Torella A. Deletion Testing of the DEGS1 Gene Should Be Part of the Diagnostic Pipeline for Hypomyelinating Leukodystrophy (HLD18). Hum Mutat. 2025;2025:3531508. doi: 10.1155/humu/3531508. Epub 2025 May 7. PMID: 40371095; PMCID: PMC12077970.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.